Sage Wins FDA Approval for ‘Game-Changing’ Postpartum Depression Treatment
Sage Therapeutics shares were up after the company won approval for the postpartum depression treatment Zulresso (brexanalone).
Lilly's Combo Therapy Succeeds In Late-Stage Lung Cancer Study
Pfizer Buys Stake In French Gene Therapy Firm Vivet
Regeneron/Sanofi Wins U.S. Approval For Expanded Use Of Skin Drug
Mylan shares sink as bleak profit outlook for 2019 sparks growth concerns
Allergan Depression Treatment Fails Studies, Shares Slip
AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study
J&J Nasal Spray Receives U.S. Approval As First New Type Of Antidepressant In Decades
Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen
GSK Cuts Six Respiratory Assets As Company Continues To Focus On Oncology Treatments
Lundbeck and Otsuka's antipsychotic drug Rexulti fails two bipolar late-stage studies
FDA Puts Partial Hold On Clinical Trials Of AbbVie's Cancer Drug
European Commission Approves Amgen's Blincyto For Ph- MRD-Positive B-Cell Precursor ALL
Lilly Receives FDA Priority Review Designation For Emgality
Amicus Therapeutics to hire 200 researchers at new gene therapy center in Philadelphia
Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo
Sanofi To Pay Regeneron $462 Million In Revised Immuno-Oncology Deal
Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV
U.S. FDA Approves Roche's Small Cell Lung Cancer Treatment Tecentriq
Takeda's Vedolizumab Achieves Superior Rates Of Clinical Remission Versus Adalimumab In First-Ever Head-To-Head Biologic Clinical Study In Ulcerative Colitis
FDA approves Dr. Reddy’s Tosymra
Astellas Breaks Into U.S. Blood Cancer Market With Approval Of Xospata For AML
Ireland Demands $1.9 Billion In Back Taxes From Perrigo
Alexion’s Ultra-Rare Kidney Disease Drug Passes Phase III With Flying Colors
FTC loses Shire appeal, losing round in fight against citizen petition abuse
French Court Dismisses Damages Claims Against Merck Over Thyroid Drug
Novartis Aims To Pump Up Cardio Business With Ionis Deal
Starboard, Opposed To BMS Deal For Celgene, Readies For Fight At April 2019 Meeting
Novo Nordisk Submits Diabetes Pill For U.S. Approval
Ad Right Top
Latest News
Novo Nordisk submits diabetes pill for U.S. approval
Novo Nordisk submitted the company's oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.
Pfizer buys stake in French gene therapy firm Vivet
Pfizer acquired a 15 percent stake in Vivet Therapeutics as well as an exclusive option to fully acquire the business, a deal that will give the New York-based pharma giant access to the French company’s experimental gene therapy for a rare genetic disorder.
Most Commented
Sorry. No data so far.
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!